This week on “The Top Line,” we explore the European biotech investment landscape.  Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector.  To learn more about the topics in this episode:  'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023 'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair   See omnystudio.com/listener for privacy information.